Alexandra Thiry

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

Jean‐Michel Molina, Jaime Andrade‐Villanueva, Juan Echevarría et al. · The Lancet · 2008 · 482 citations

Treatment And Prevention, Antiviral Drug Development, Clinical Trials +9

Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV

Kathleen Squires, Adriano Lazzarin, Jos M. Gatell et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2004 · 299 citations

A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients

Ting‐Tsung Chang, Robert G. Gish, Stephanos J. Hadziyannis et al. · Gastroenterology · 2005 · 248 citations

Hepatology, Viral Hepatitis, Hepatitis B +6

Results of a Phase 2 Clinical Trial at 48 Weeks (AI424-007): A Dose-Ranging, Safety, and Efficacy Comparative Trial of Atazanavir at Three Doses in Combination with Didanosine and Stavudine in Antiretroviral-Naive Subjects

Ian Sanne, Peter J. Piliero, Kathleen Squires et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2003 · 223 citations

Identification of I50L as the Signature Atazanavir (ATV)–Resistance Mutation in Treatment‐Naive HIV‐1–Infected Patients Receiving ATV‐Containing Regimens

Richard J. Colonno, Ronald E. Rose, C. McLaren et al. · The Journal of Infectious Diseases · 2004 · 145 citations · Full text

Hiv-1 Protease, Atv‐containing Regimens, Protease Inhibitor +14